Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric acute promyelocytic leukemia treatment study
NL-OMON39899Phase 3Active, not recruiting
- Sponsor
- SKion
- Start
- Mar 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of tretinoin, arsenic trioxide, gemtuzumab ozogamicin, cytarabine, mercaptopurine and 1 more in Acute promyelocytic leukaemia (APL) (3 arms), sponsored by SKion. Primary endpoints: Achievement of molecular complete remission, Duration of remission and 7 more. Started Mar 2011; status: active, not recruiting.
02
Drugs
tretinoinarsenic trioxidegemtuzumab ozogamicincytarabinemercaptopurine
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on NL-OMON39899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39899.